Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study

Switching from GLP-1 receptor agonists to tirzepatide improved liver and metabolic measures in patients with type 2 diabetes at high risk of MASLD, especially in those with high baseline fibrosis risk. In a retrospective study of 182 such patients, HbA1c, body weight, and liver enzymes fell over 6 months, and a liver fibrosis index improved significantly only in the high-risk group.

Journal article — multicenter retrospective secondary analysis. Population: patients with type 2 diabetes at high risk of MASLD from the Hokkaido-TZP study who switched from GLP-1RAs to tirzepatide. Sample size: 182 patients. Follow-up: 6 months. Interventions: tirzepatide.

During 6 months of follow-up, switching from GLP-1RAs to tirzepatide significantly reduced HbA1c, body weight, and liver enzymes in 182 patients. HSI decreased in both low-risk and high-risk groups, but FIB-4 index decreased significantly only in the high-risk group (P < 0.001). Improvements in hepatic indices were not correlated with changes in BMI or HbA1c. Baseline HSI showed a positive correlation with change in FIB-4 index (ρ = 0.234, P = 0.005).

Researchers studying tirzepatide will be interested because this real-world analysis suggests switching from GLP-1RAs to tirzepatide may improve hepatic fibrosis risk scores in type 2 diabetes patients at high MASLD risk, particularly those with high baseline fibrosis risk, independently of weight loss. The paper does not establish causality, provide dosing guidance, or show histologic endpoints, so it should be interpreted as hypothesis-generating evidence.

Key findings

• HbA1c, body weight, and liver enzymes significantly decreased after switching to tirzepatide.
• Hepatic Steatosis Index decreased in both low-risk and high-risk groups.
• Fibrosis-4 index decreased significantly only in the high-risk group (P < 0.001).
• Improvements in hepatic indices were not correlated with changes in body mass index or HbA1c.
• Baseline HSI was positively correlated with change in FIB-4 index (ρ = 0.234, P = 0.005).

Limitations

• Retrospective design cannot establish causality and is vulnerable to confounding.
• Secondary analysis of a selected subpopulation may introduce selection bias.
• No control arm continuing GLP-1RA therapy, so the incremental effect of switching could not be directly quantified.
• Six-month follow-up is short for assessing liver fibrosis progression.

The record

• Journal: Journal of diabetes and its complications: 109391
• Published: 2026-08-14
• PMID: 42618422 — DOI: 10.1016/j.jdiacomp.2026.109391
• Author countries: Japan

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….